SCHEMBL6120773

SCHEMBL6120773

CCN(CC)c1nc(C)c(-c2csc(Nc3cc(C(N)=O)ccc3OC(C)C)n2)s1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 13/20 0.47
MAPT P10636 13/20 0.47
KMT2A Q03164 13/20 0.47
ALDH1A1 P00352 10/20 0.47
KDM4E B2RXH2 9/20 0.47
HTT P42858 8/20 0.47
GAA P10253 8/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
HPGD P15428 6/20 0.47
LMNA P02545 6/20 0.47
TDP1 Q9NUW8 2/20 0.46
ALOX12 P18054 1/20 0.46
CFTR P13569 2/20 0.44
HSD17B10 Q99714 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8738815 0.91 MEN1 (0.46) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL6114193 0.87 MEN1 (0.58) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL8738028 0.87 MEN1 (0.56) MEN1MAPTKMT2AALDH1A1KDM4E
Bromide SCHEMBL6113998 0.86 MEN1 (0.57) MEN1MAPTKMT2AALDH1A1KDM4E
Bromide SCHEMBL6113988 0.86 MEN1 (0.56) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL6113996 0.85 MAPT (0.48) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL6122343 0.85 TRPV4 (0.49) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL8738788 0.85 MAPT (0.46) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL6114066 0.85 MEN1 (0.49) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL6113997 0.84 TDP1 (0.48) MEN1MAPTKMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MEN1 2298/4885MAPT 3531/4885KMT2A 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.